Introduction
============

HCC is one of the most common malignant cancers in China, which accounts for approximately 90% of all primary liver cancers (PLC). Surgery, orthotopic liver transplantation (OLT), hepatic-artery chemoembolization (TACE), percutaneous intra-tumor ethanol injection (PEI), hepatic artery ligation (HAL) with catheterized chemotherapy, and molecularly targeted therapy are the common therapeutic treatments for HCC [@B1], [@B2]. However, treating HCC remains difficult and challenging. Sorafenib has been shown to improve survival in the treatment of HCC. However, only a limited number of patients have responded beneficially [@B3]. Prognosis of HCC remains poor, and HCC-related mortality is high [@B4].

Nowadays, immunotherapy using DC-based antigen-specific CTLs has been used in clinical trials for the treatment of various malignant tumors [@B5]-[@B7]. DCs from the peripheral blood of patients were transfected with recombinant adenoviruses containing TAAs and produced high levels of IL-12 in response. Mature DCs co-cultured with T cells induced the activation of CTLs and promoted a tumor-killing effect of antigen-specific T cells that may provide effective adjuvant therapy for malignant tumors. Several studies have focused on the study of DC-based antigen-specific immunotherapy for HCC. Bray investigated the response of AFP-derived peptide-pulsed DC on immunity in patients with HCC [@B8]. Pardee compared the efficacy of antigen-specific CD8+ and CD4+ T cells using different forms of AFP fragments [@B9]. Zhou et al. used Hep3B cells that were transduced with recombinant adenoviruses carrying a human IFN-α promoter and an IFN‑γ gene to improve the effect of tumor-specific CTL against HCC [@B10]. O\'Beirne et al. assessed the function of GPC-3 specific T cells in HCC [@B11]. Moreover, DC-CTLs therapy additionally held promise for the treatment of other malignant tumors, including non-small cell lung cancer (NSCLC) [@B12] and prostate cancer [@B13].

Therefore, it is important to determine the appropriate TAAs for DC activation and DC-CTLs therapy [@B14]. Several TAAs, such as TP53, Survivin, human telomerase reverse-transcriptase (hTERT), WT-1, and VEGFR2, frequently express on the cell surface of many malignant cancers including HCC and have been identified as promising TAAs for *T cell recognition* or DC-based immunotherapy [@B15]-[@B18]. Although TAAs, including TP53, hTERT, and Survivin, have been used as DC vaccines in clinical trials against tumors [@B19]-[@B21], it is still uncertain whether these antigen-primed DCs can be used for enhancing the response of CTLs in patients with HCC.

During our prophase research [@B22], we preliminary evaluated the changes of Tregs, MDSCs, AFP, CA19-9, CA242 and CA724 in five malignant tumors. To further study the comprehensive potential value of DC-CTL therapy for HCC patients, we investigated the activities of expanded and activated DCs and CTLs; analyzed the changes in the serological index and levels of CD3, CD4, CD8 and Tregs; and assessed the clinical response of OS, PFS and quality of life in HCC patients treated with DC-CTLs therapy.

Materials and Methods
=====================

Patients
--------

A total of 42 pathologically diagnosed HCC patients have signed informed consent forms approved by the Department of Health of Chinese PLA, and they received immunotherapy at Eastern Hepatobiliary Surgery Hospital from January 2012 to December 2014.Twenty-six other patients, who were enrolled as control group, did not receive DC-CTLs immunotherapy. The study is non-randomized because we don\'t have enough patients to be randomized into two arms at the same time. The inclusion criteria included as follows:

1\) The diagnosis was confirmed by pathology of HCC

2\) Difficult or refusal to undergo surgery

3\) Child-Pugh score \<=9 (Class A or B)

4\) Clinical Oncology Group Eastern (ECOG) score of 0, 1

5\) Liver, kidney and blood tests meet the following criteria:

WBC\>4×10^9^/L, Neutrophils cells\>1×10^9^/L, Lymphocyte cells\>1×10^9^/L, Hemoglobin\>=100g/L and Platelet\>=80×10^9^/L. The prothrombin time is in a reference range or not extends for more than 3 seconds. Urea nitrogen and serum creatinine do not exceed 1.5 times of the upper limitation.

6\) Sign the informed consent form before joining into this study.

Patients were excluded from the study based on the following criteria:

1\) Autoimmune disease or organ transplant history undergoing immunosuppressive therapy

2\) Human immunodeficiency virus (HIV) infection, syphilis infection

3\) Image evidence of positive or infected blood culture

4\) Cell therapy allergies history, cytokines (such as interleukins) allergic history

5\) Uncontrolled heart, lung, kidney, digestion, nerve, metabolism, infectious diseases, mental illness, etc. or other serious diseases

6\) Pregnant women

As shown in Table [1](#T1){ref-type="table"}, 16 patients (n=5 in the control group; n=11 in the DC-CTL therapy group) underwent adjuvant radiation treatment, and 52 patients (n=21 in the control group; n=31 in the DC-CTL therapy group) received TACE therapy.

Construction and production of recombinant adenoviruses that encode tumor-associated antigens
---------------------------------------------------------------------------------------------

A replication-defective adenovirus containing the expression cassette of the required TAAs (TP53, hTERT and Survivin) was constructed, purified, and titrated according to the procedure described previously [@B23]. In brief, each expression cassette of the TAA was inserted into the shuttle vector of the recombinant adenoviral system and placed into the E1 region of the adenoviral genome. Then, the recombinant adenoviruses were purified by high-performance liquid chromatography. Titers of the purified adenoviruses were determined by plaque assays of the tissue culture infectious dose 50 methods and shown as plaque-forming units per milliliter (pfu/ml). The sequences of TP53, hTERT and Survivin are recorded in Supplementary Table [S1](#SM0){ref-type="supplementary-material"}.

Generation of mature DCs with cancer-associated antigens
--------------------------------------------------------

Approximately 40-60ml of white cells was obtained from each patient using a blood-cell separator (FreseniusKabi, Germany). The yield of peripheral blood mononuclear cells (PBMCs) ranged from 1×10^9^-3×10^9^ cells. Cells were washed twice with AIM-V cell-culture medium (Gibco, America), transferred into culture flasks, and cultured for 2 hours. Adherent cells were used for induction of DCs by adding 100ng/ml GM-CSF (PeproTech, America) and 100ng/ml IL-4 (PeproTech, America) to the AIM-V cell-culture solution. Remaining non-adherent cells from the remainder of the PBMCs were stored at -80℃ and thawed for co-cultivation. On day 6, recombinant adenoviruses encoding different TAAs were used to infect DCs (MOI=10). On day 7, IL-1β (25 ng/ml; Novoprotein, China) and TNF-α (100 ng/ml; Novoprotein, China) were added into the culture for maturation of DCs.

Preparation of CTLs
-------------------

On day 8, TAAs loaded DCs were co-cultured with T cells at a DC/T-cell ratio of 1:20, stimulated with the CD3 monoclonal antibody (mAb; 50ng/ml; Novoprotein, China), pre-coated onto plastic plates, and amplified by IL-2 (500IU/ml; Quangang Pharmaceutical Co., China). On day 22, cells were infused back into patients via intravenous injection. For each treatment, approximately 3×10^7^ cells/kg body weight activated T cells were infused. The viability of cells should be over 95%.

Immunophenotyping of immune cells
---------------------------------

Immune markers CD14, CD80, CD83, CD86 and CD11c for DC cells; CD3 and CD8 for CTL cells; and CD137 and CD69 (24h) for activated T cells were analyzed by flow cytometry on FC500 and Guava EasyCyte™ flow cytometers (Beckman Coulter, America; Merck Millipore, Germany). In addition, immune indicators were detected using the peripheral blood samples of patients before and after DC-CTLs treatments, and were accessed by the Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (China). Monoclonal antibodies anti-CD3, -CD4, and -CD8 were used to evaluate T lymphocyte subgroups, and CD4+/CD25+/ CD127lo/- was used to evaluate Tregs. The proportion of Tregs was calculated by the ratio of CD25hiCD127lo/- cells to CD4+ cells. Flow cytometry data were analyzed by CXP software and GuavaSoft™ 3.1.1.

Cytokine analysis via intracellular cytokine staining (ICS)
-----------------------------------------------------------

Samples were divided into one unstimulated group (negative control) and two stimulated groups (positive control and DC-CTLs group). Samples in the stimulated groups were cultured with a 1X cell stimulation cocktail (eBioscience, America) containing phorbol 12-myristate 13-acetate (PMA), ionomycin, brefeldin A and monensin for 4-6 hours. Subsequently, the production of different cytokines, including IFN-γ, TNF-α, and IL-4, was detected using the Intracellular Fixation &Permeabilization Buffer Set Kit (Beckman Coulter, America).

IFN-γ detection by ELISA, ELISPOT and Cytometric Bead Array (CBA) assay
-----------------------------------------------------------------------

To assess the activation of antigen-specific T cells, levels of IFN-γ in infused cells were detected by ELISA, human IFN-γ ELISPOT kit (Dakewe, Shenzhen, China) and CBA assay (BD, America). CBA is a multiplexed assay that provides the ability to quantify multiple proteins within a given sample. The principle of CBA assays is to capture a soluble set of analytes with beads of known size and fluorescence, and sandwich complexes (capture bead + analyte + detection reagent) are formed, which can be measured using flow cytometry.

Quality monitoring
------------------

Infused cells were cultured to detect bacterial endotoxin and mycoplasma levels. In accordance with the Chinese Pharmacopoeia, the level of endotoxin was calculated using the following formula: L=K/M. L is the threshold level of bacterial endotoxin expressed in EU/mg or EU/u. K is the maximum acceptable endotoxin dosage per kilogram of body weight per hour in the prescribed route of administration in EU/kg/h. The default value was K=5EU/kg/h. M is the maximum acceptable dosage in humans per kilogram of body weight per hour. Weight was calculated as 60kg, and injection time (≤1h) was calculated as 1h. Our final product volume was 300ml, body weight was calculated as 60kg, and the time of infusion was 0.5 h. Therefore, the threshold of L was approximately 0.5EU. Microbial detection and Gramstaining were performed by a BacT/ALERT® 3D instrument (Biomerieux, America) and a PREVI® Color Gram staining system (Biomerieux, America). Mycoplasma testing was conducted using an ELISA method.

Detection of biochemical parameters and serological tumor markers
-----------------------------------------------------------------

Levels oftotal bilirubin (TB), alanine transaminase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (AKP), serological tumor markers such as alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA199), and the percentage of alpha fetoprotein L3 (AFP-L3%) were evaluated before and after immunotherapy in patients with HCC. Recommended cutoff-values for diagnostic purposes were 5.1-18.8μmol/L for TB, 0-41 U/L for ALT, 0-37 U/L for AST, 5-61 U/L for GGT, 35-129 U/L for AKP, 0-20 μg/L for AFP, 0-10 μg/L for CEA, 0-39 U/ml for CA199 and 0-10% for AFP-L3%.

Assessment of quality of life (QoL)
-----------------------------------

The EORTC QLQ-C30 questionnaire was designed by the European Organization for Research and Treatment of Cancer (EORTC) to assess specific quality of life issues relevant to cancer patients. The QLQ-C30 (version 3.0) measures health-related QoL from prior week using a global QoL scale, which includes five functional scales, three symptom scales, one quality of life scale, and six other unique items. Scale scores (range: 0-100) are re-scaled mean scores of their individual component items. Higher global QoL/functional scale scores indicate better QoL, however, higher symptom scale/item scores indicate a higher level of symptomatology. Scores from these scales were assessed using Chi-square tests, with significant results limited to *p* value \<0.05. Telephone consultations were conducted for each patient regularly to complete the EORTC QLQ-C30 questionnaire one month after each cycle of DC-CTL treatment [@B24], [@B25].

Follow-up and survival rates
----------------------------

OS was defined as the time from the date of enrollment to the date of death due to the tumor or last follow-up. PFS was defined as the date of definitive treatment to the date of tumor recurrence or date of the last follow-up. Patients who were lost to follow-up were considered censored at their date of their last follow-up.

Statistical analysis
--------------------

Results were presented as the mean ± standard deviation (mean ± SD). All data were analyzed by SPSS 22 software (SPSS, Chicago, IL, USA). Differences in demographic and clinical variables of the two groups were tested using the Pearson χ^2^ test. The Kaplan-Meier method was used to analyze PFS and OS. The log-rank test was used to compare differences in Kaplan-Meier estimates for each group. The Cox proportional hazards regression model was used for univariate analysis. Statistical significance of immune-markers was evaluated by a paired t-test. *P* values\<0.05 were considered as statistically significant.

Results
=======

Patient characteristics
-----------------------

The present study comprised a retrospective analysis of 68 patients (59 males and 9 females) with a median age of 57 (range: 27-80) years. All patients had a confirmed diagnosis of HCC between January 2012 and December 2014 with follow-ups until December 2015 and were divided into two cohorts (a control group and a DC-CTL group). As shown in Table [1](#T1){ref-type="table"}, demographic data were comparable between the two groups. The data also indicated that there were no statistically significant differences between the two groups in terms of variables such as, sex, age, TNM stage, and recipient of either radiation therapy or TACE (*p*\>0.05). Figure [1](#F1){ref-type="fig"} showed the detailed schedule from enrollment, treatment, blood collection, cell separation, cell culture, quality monitoring and cell infusion.

Activities of expanded and activated DCs
----------------------------------------

The differences of immune phenotypes between immature DCs and mature DCs, including levels of CD80, CD86, CD83, CD11c and CD14, were analyzed by flow cytometry as shown in Figure [2](#F2){ref-type="fig"}. Compared with immature DCs (im-DCs), mature DCs (m-DCs) highly expressed various DC markers, including the costimulatory proteins CD80 (88.55%±4.07%) and CD86 (91.16%±7.32%). Mature DCs also have up-regulated level of the DC activation marker CD83 (87.40%±5.08%). Additionally, when mature DCs evolved from monocytes, they lost the expression of CD14 (CD14 negative or CD14- DCs). CD11c, a type-I transmembrane protein, is found at a high level on most human DCs (95.24%±4.97%). In Figure [2](#F2){ref-type="fig"}, the flow cytometric dot plots showed the results from one representative experiment, and the barplot described the statistical analysis of the percentages of positive cells. DCs exhibited high-level expression of CD80, CD86, CD83 and CD11c on day 8, which confirmed the maturation of DCs after cultivation.

Activities of expanded and activated DC-CTLs
--------------------------------------------

We consistently tested the quality of the T cells by detecting the percentage of the activation markers CD69, CD28, and CD137 and the percentage of CD3+CD8+ CTLs. Among the cultivated CD3+ T cells, the population of activated CD69+ after 24h and CD28+ and CD137+ T cells after day 14 reached 91.16%±1.03%, 93.00%±5.49%, and 23.80%±4.57%, and CD3+CD8+ CTLs reached 87.71%±2.32%, respectively, which were higher than those in CIKs (CD69+: 31.23%±3.15%; CD28+: 51.87%±5.53%; CD137+: 2.19%±1.31%; CD8+: 60.4%±4.86%) and DC-CTLs without TAAs stimulation (CD69+: 54.3%±2.87%; CD28+: 62.13%±7.36%; CD137+: 6.07%±0.23%; CD8+: 73.83%±4.71%).

Production of intracellular cytokines was measured by ICS. IFN-γ and TNF-α exhibited higher levels during *in vitro* cultivation, and the proportion of T cells expressing IFN-γ and TNF-α was 17% and 19.3%, respectively, compared to unstimulated T cells and Ad-Blank DC-CTLs stimulated with a cell stimulation cocktail (Figure [3](#F3){ref-type="fig"}). The percentage of T cells that secreted IL-4, which generally decreases the production of IFN-γ, was less than 1%.

Furthermore, antigen-specific T cell responses were measured by ELISA and CBA assay. The production of IFN-γ reached 6756.53±145.96 pg/ml in re-fused cells compared with 1440.97±11.89 pg/ml in unstimulated controls (estimated *via* ELISA). In addition, the CBA assay showed that levels of IFN-γ were significantly higher in infused cells (7308.53±527.60 pg/ml) than in unstimulated controls (1145.94±179.16 pg/ml). The Elispot experiment showed that the DC-CTL group exhibited an average of 142 spots which highly increased spot numbers compared to the negative control with very few spots or none at all.

Quality monitoring
------------------

Cells were cultured for the detection of bacterial endotoxin and mycoplasma levels. All cultured samples met the release criteria for infusion.

Analysis of quality of life
---------------------------

A pre- and post-treatment evaluation of the health-related quality of life in patients with HCC was conducted. During analysis of the EORTC QLQ-C30 questionnaire for the control group, patients who received conventional therapy had significantly higher scores for nausea and emesis, appetite loss, and diarrhea than pretreatment patients (p\<0.05). Strikingly, the global health/quality of life score improved significantly in patients who underwent DC-CTLs therapy. Collectively, there was a statistically significant difference in life quality between the two groups (p=0.017), and the physical-functioning (PF) scale showed a strong improvement during the course of therapy (p=0.005). Fatigue, nausea and emesis, dyspnea, insomnia, constipation, and diarrhea decreased slightly during the course of immunotherapy but not significantly (Figure [4](#F4){ref-type="fig"}). The increased scores in the function scale/overall QoL and the decreased scores in the symptom scales showed an improved quality of life for patients with HCC who underwent DC-CTLs treatment.

Change of serological index
---------------------------

Considering the possible presence of clinical heterogeneity among patients, we employed Chi-square tests to evaluate clinical response. During analysis of the serological index of the DC-CTL group, we observed that the mean levels of AFP, AFP-L3, ALT, and CA199 were significantly lower after DC-CTL treatment (p=0.0437, p=0.0471, p=0.0037, p=0.0262, respectively) than the mean levels in pre-therapy patients. Patients who underwent DC-CTL therapy had lower average serum levels of AST and TB, although these differences were not highly significant (p\>0.05). Nevertheless, there were no significant differences in these serological indexes before and after treatment in the control group (Figure [5](#F5){ref-type="fig"}a).

Treg cells decreased after DC-CTL immunotherapy
-----------------------------------------------

Subsequently, we investigated the changes of immune indicators, including CD3, CD4, CD8, and Treg, pre- and post-DC-CTL treatment. The 8 of 11 patients who received DC-CTL therapy showed a lower percentage of Tregs (\<10%), and Tregs (%) in 26 of 42 patients decreased after treatment. The proportion of Treg cells reduced significantly in patients undergoing either radiotherapy or TACE (p=0.001422). Moreover, percentages of CD3+CD4+ T lymphocytes decreased significantly (p\<0.0001), and the number of CD3+CD8+ T lymphocytes in the peripheral blood tended to increase (p\<0.0001). In comparison, there were no statistically different changes in CD3+ cells (Figure [5](#F5){ref-type="fig"}b).

Overall survival and progression-free survival
----------------------------------------------

Clinical factors were further evaluated by Cox proportional hazards regression analysis. Notably, DC-CTLs treatment showed a significant association with PFS and OS in the univariate analysis, although sex, age, TACE, radiotherapy, and TNM stages were not independent prognostic factors for OS and PFS (Table [2](#T2){ref-type="table"}).

We subsequently investigated whether this observation was related to DC-CTL treatment. Patients had periodic follow-up until December 2015. The median OS and PFS were 8.2 months and 4.3 months, respectively, for the control group and 12.8 months and 9 months, respectively, for the DC-CTL treatment group. Patients treated with DC-CTLs therapy showed a statistically significant PFS and OS curve compared with the control group (OS: p=0.016; PFS: p\<0.0001; Figure [6](#F6){ref-type="fig"}a).

In addition, adjunctive therapies (TACE therapy or radiotherapy) could be associated with the prognosis of patients with HCC, while they may not be regarded as independent prognostic factors in Cox proportional hazards regression analysis. Therefore, we further compared OS and PFS in the TACE and radiotherapy subgroup. In a follow-up comparison of 1-year for OS and PFS between the TACE-alone and TACE+DC-CTL groups, OS increased from 42.9% to 64.5%, and PFS rates increased from 23.8% to 38.7%. Similarly, one-year OS rates increased from 20% to 45.5% in the radiotherapy + DC-CTL group compared with the radiotherapy-alone group. The median OS and PFS were 4.93 months for patients undergoing radiotherapy alone and 11.47 months and 7.67 months for those undergoing radiotherapy along with DC-CTL treatment (Figure [6](#F6){ref-type="fig"}b). Additionally, OS and PFS were 9.33 months and 3.57 months, respectively, for the TACE-alone group and 12.9 months and 9.2 months, respectively, for the DC-CTL treatment group. Patients in the DC-CTL group showed a statistically significant PFS and OS curve, respectively (PFS: p=0.017, p=0.002; OS: p=0.042, p=0.035; Figure [6](#F6){ref-type="fig"}c).

Safety
------

Side effects were recorded in 68 cases. There were no severe or unusual side effects, except for temporary fever. In total, 27 of 68 cases developed a fever during immunotherapy, and body temperature ranged from 37.5-40°C. Most of these patients recovered without any treatment. No side effects on the liver and kidney were found.

Discussion
==========

Thus far, a number of agencies have carried out clinical trials and made progress in the use of DC-CTLs therapy in the treatment of metastatic renal-cell carcinoma, gastric cancer, and other malignancies [@B26]. Previous research reported that DC-based antigen-specific immunotherapy still faces some obstacles, including inefficient cultivation of DCs, TAAs alteration, and the presence of extrinsic regulators, including Tregs [@B14], [@B27]. Our study showed that a cocktail of TAAs-loaded DCs could enhance the response of CTLs against HCC.

In this study, we utilized automatic blood sampling via a blood-cell separator to improve the harvesting of DCs. This method is typically used in treatment of leukemia [@B28], [@B29], but it is less often reported in immunotherapy. According to the parameter setting, white cells are collected within several circuits, while the remainder of the blood components is returned to the patient via a returning chamber. In total, approximately 1×10^9^-3×10^9^ PBMCs can be obtained by Ficoll cell separation solution. Therefore, the number of DCs obtained from blood samples was significantly higher than those obtained by venipunctures. At present, we can collect 1×10^9^-3×10^9^ PBMC cells per 40-60ml of white blood cells via the blood cell separator as well as acquire approximately 1×10^8^ DCs per 40-60ml of white cells *in vitro*, which enables us to harvest sufficient DCs for cultivation. In addition, we compared DC markers between healthy donors and patients. Levels of maturation achieved by DCs were lower for patients than for donors. We determined that it was better to compare the change of DCs in the same patient because patients\' DCs could not completely recover after *in vitro* stimulation.

Cytokines frequently play an important role in immunity, are involved in tumor progression, and provide crucial information regarding activated DC-CTLs. Several studies have suggested that the expression of IFN-γ and TNF-α in T cells is associated with the response of tumor-specific T cells, and this produces significant anti-tumor effects by inhibiting tumor-cell proliferation and promoting tumor cell apoptosis. Production of TNF-α and IFN-γ exert a strong synergistic boost to antigen-specific immune responses during DC-CTL immunotherapy [@B30]-[@B32]. Others indicated that the presence of IL-4 could markedly impair CD8+ T cell expansion and additionally inhibit IL-12 production by DCs and IFN-γ secretion [@B33]-[@B35]. Herein, we demonstrated that our approach increased expression levels of IFN-γ and TNF-α, indicating that antigen-specific T cells were activated.

Studies have confirmed the benefits and the safety aspects of DC-CTLs therapy for patients with HCC. We tested the quality of the infused cells and used a combination of indicators, including immune indicators, serological tumor markers, QoL, OS, PFS, and observed side effects, for an in-depth assessment of the treatment. We greatly decreased the proportion of Tregs, which contain potent anti-tumor immune-suppressive function in the immune system [@B36], [@B37]. A high level of Tregs is a prognostic factor, and it is regarded as an adverse factor in patients with malignant tumors. Compared with the Tregs proportion in control group, a higher percentage of Tregs was found in patients with HCC, possibly due to immune-dysfunction prior to treatment. Notably, in our study, a robust immune response was observed in patients with a reduced proportion of Tregs and CD4+ T cells as well as an increased proportion of CD8+ T cells. A series of serum biomarkers, such as AFP, AFP-L3, ALT, and CA199, are routinely tested in patients with HCC to reflect the clinical response after DC-CTLs therapy. AFP-L3 is calculated as the proportion of AFP-L3 over total AFP levels, which can be used with AFP as biomarkers to indicate HCC [@B38]. Previous studies have suggested that high serum AFP-L3% levels indicated a poor prognosis for HCC patients [@B39], [@B40]. Similarly, the serum level of CA19-9 is also found to be elevated in HCC patients, and it is considered as a predictor of survival for HCC [@B41]. In addition, a high serum level of ALT is commonly reported to indicate the status of liver injury [@B42]. Therefore, these clinical indexes may have significant prognostic value in HCC patients with low serum concentrations. A decrease of these clinical indicators simultaneously after DC-CTL treatment may reflect a therapeutic effect of this treatment on HCC. The side effects and toxicity of DC-CTLs therapy were mild and easily controllable. The response of DC-CTLs immunotherapy is well tolerated by patients who were unable or unwilling to experience the adverse side effects of conventional therapies. The results of DC-CTL treatment showed that the treatment significantly improved the global health of patients (QoL score, p-value\<0.05).

In this study, we measured long-term effects of DC-CTLs therapy on 68 patients. However, similar studies are needed in the future with a larger number of patients suffering from different types of tumors to further investigate the clinical response of this approach. We have developed an immunotherapeutic strategy for the treatment of patients with HCC, but further optimization strategies are still required. Previous report has elaborated on neo-antigens in cancer immunotherapy and personalized antigens for cancer treatment [@B43]. Therefore, at present, further optimization of protocols for cell isolation and standardization of the cocktail of TAAs is being attempted. A novel cocktail of TAAs, such as ERBB1, ERBB2, ERBB3, ERBB4, MAGE-A1, MAGE-A3, GPC3 and MUC1, as well as several personalized antigens for patients, such as the use of AFP or CEA antigens for therapy in patients with AFP+ or CEA+, are being investigated in our further studies to improve the anti-tumor effects of DC-CTLs immunotherapy and prolong survival of patients.

In summary, we improved the existing protocol for harvesting high-quality sufficient DCs, and we investigated the effect of DC-CTLs therapy on patients with HCC. Our results showed that it significantly reduced the proportion of Tregs as well as several specific clinical indexes, including AFP, AFP-L3, ALT and CA19-9. The DC-CTLs treatment may preserve or improve the quality of life in patients who have invasive cancers. These findings indicate the role of the DC-CTLs therapy in patients with HCC.

Supplementary Material {#SM0}
======================

###### 

Supplementary Table S1.

###### 

Click here for additional data file.

This work was supported by the National Natural Science Foundation of China (grant numbers 81672997, 31601075, 81573023 and 81301307), and the Capacity Building Project of Shanghai Engineering Research Center (16DZ2281000).

Compliance with Ethical Standards
=================================

The trial was approved by the Committee on Medical Ethics of Eastern Hepatobiliary Surgical Hospital. All patients in our trial have signed informed consents.

AFP

:   Alpha fetoprotein

AKP

:   Alkaline phosphatase

ALT

:   Alanine transaminase

AST

:   Aspartate aminotransferase

CA199

:   Carbohydrate antigen 19-9

CBA

:   Cytometric bead array

CEA

:   Carcinoembryonic antigen

DC-CTLs

:   Dendritic cell-cytotoxic T lymphocytes

EORTC

:   The European Organization for Research and Treatment of Cancer

GGT

:   Gamma-glutamyl transferase

HAL

:   Hepatic artery ligation

HCC

:   Hepatocellular carcinoma

hTERT

:   Human telomerase reverse-transcriptase

ICS

:   Intracellular cytokine staining

OLT

:   Orthotopic liver transplantation

OS

:   Overall survival

PBMCs

:   Peripheral blood mononuclear cells

PEI

:   Percutaneous intra-tumor ethanol injection

PF

:   Physical-functioning

PFS

:   Progression-free survival

PLC

:   Primary liver cancers

PMA

:   Phorbol 12-myristate 13-acetate

QoL

:   Quality of life

TAAs

:   Tumor-associated antigens

TACE

:   Transarterial chemoembolization

TB

:   Total bilirubin

Tregs

:   Regulatory T cells.

![**The flow chart of the process of DC-CTLs therapy.** The detailed schedule depicted enrollment, treatment, blood collection, cell separation, cell culture, quality monitoring and cell infusion.](jcav09p0275g001){#F1}

![**Surface phenotype analysis of DCs.** Cells were harvested and processed for staining with the antibody, as indicated. The staining of markers is shown, and the percentage of positive cells is stated (\*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, \*\*\*\*p\<0.00005). The phenotypic analyses of mature DCs on day 8 were compared with immature DCs on day 4. The biomarkers included CD14, CD80, CD83, CD86, and CD11c. The red peak represents the isotype group. The barplot showed the percentage of cells expressing each biomarker. The proportion of positive cells was calculated on Y-axis.](jcav09p0275g002){#F2}

![**Detection of intracellular IFN-γ, TNF-α, IL-4 and IFN-γ concentrations in the supernatant.** Dot plots show the proportion of T cells expressing IFN-γ, TNF-α, and IL-4. The top left plot represents the gating strategy. The bottom left plot represents the isotype group. The 2^nd^ to 4^th^ plots on the top represent unstimulated T cells, the 2^nd^ to 4^th^ plots in the middle represent the Ad-Blank group (the recombinant non-proliferative adenovirus without any expression cassettes of tumor-associated antigens) stimulated with the cell stimulation cocktail, and the 2^nd^ to 4^th^ plots on the bottom represent the production of cytokines by DC-induced antigen-specific CTL cells.](jcav09p0275g003){#F3}

![**Change in quality of life.** The bar plot describes various scales for all the tumor patients measured at two visit times. The black bar represents the pre-immunotherapy visit, and the white bar indicates the last follow-up time after DC-CTL treatment. The X-axis represents the key scales of QLQ-C30, including, physical functioning (PF), role functioning (RF), emotional functioning (EF), cognitive functioning (CF), social functioning (SF), pain (PA), fatigue (FA), nausea and emesis (NV), dyspnea (DY), insomnia (SL), appetite loss (AP), constipation (CO), diarrhea (DI), financial difficulties (FD), and quality of life (QoL). The scale score was calculated and indicated on Y-axis. \*Statistically significant differences (\*p\<=0.05, \*\*p\<=0.005)](jcav09p0275g004){#F4}

![**Change in clinical and immune indicators** a. The boxplot describes various clinical indicators for all patients, before and after DC-CTL treatment. The X-axis represents crucial clinical indicators, including ALT, AFP, CA19-9, and the percentage of alpha-fetoprotein L3 (AFP-L3(%)). These values were calculated and indicated on the Y-axis (\*p\<0.05, \*\*p\<0.005). b. Changes in immune indicators, including CD3+, CD3+CD4+, CD3+CD8+, and Tregs, before and after DC-CTL treatment compared with patients in the control group (\*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005).](jcav09p0275g005){#F5}

![**Survival analyses of patients with HCC** Survival analyses were performed to estimate the prognosis of patients with HCC. The Kaplan-Meier method was used to compare survival rates between patients undergoing DC-CTL therapy combined with adjuvant strategies (the DC-CTL group) and those undergoing radiotherapy or TACE therapy alone (the control group). \*Statistically significant differences (\*p\<0.05, \*\*p\<0.005). a. OS curves and PFS curves for all patients. b. OS curves and PFS curves for the radiotherapy subgroup. c. OS curves and PFS curves for the TACE therapy subgroup.](jcav09p0275g006){#F6}

###### 

Demographics and clinical characteristics

  --------------------------------------------------------------------------------------
                   Cases (%)\   Control group (%)\   DC-CTL group (%) (n=42)   P-Value
                   (n=68)       (n=26)                                         
  ---------------- ------------ -------------------- ------------------------- ---------
  Sex                                                                          0.745

  Male             59 (86.8%)   23 (88.5%)           36 (85.7%)                

  Female           9 (13.2%)    3 (11.5%)            6 (14.3%)                 

  Age                                                                          0.720

  \<57             40 (58.8%)   16 (61.5%)           24 (57.1%)                

  \>=57            28 (41.2%)   10 (38.5%)           18 (42.9%)                

  Median (range)   57 (27-80)   52 (30-80)           57 (27-78)                

  Radiotherapy                                                                 0.511

  Yes              16 (23.5%)   5 (19.2%)            11 (26.2%)                

  No               52 (76.5%)   21 (80.8%)           31 (73.8%)                

  TACE therapy                                                                 0.511

  Yes              52 (76.5%)   21 (80.8%)           31 (73.8%)                

  No               16 (23.5%)   5 (19.2%)            11 (26.2%)                

  T stage                                                                      0.596

  T2               11 (16.2%)   3 (11.5%)            8 (19.0%)                 

  T3               49 (72.1%)   19 (73.1%)           30 (71.4%)                

  T4               8 (11.8%)    4 (15.4%)            4 (9.5%)                  

  N stage                                                                      0.811

  N0               42 (61.8%)   17 (65.4%)           25 (59.5%)                

  N1               22 (32.4%)   8 (30.8%)            14 (33.3%)                

  N2               4 (5.9%)     1 (3.8%)             3 (7.1%)                  

  M stage                                                                      0.128

  M0               49 (72.1%)   16 (61.5%)           33 (78.6%)                

  M1               19 (27.9%)   10 (38.5%)           9 (21.4%)                 

  TNM stage                                                                    0.293

  II               35 (51.5%)   12 (46.2%)           23 (54.8%)                

  III              14 (20.6%)   4 (15.4%)            10 (23.8%)                

  IV               19 (27.9%)   10 (38.5%)           9 (21.4%)                 
  --------------------------------------------------------------------------------------

###### 

Univariate analysis of OS and PFS in patients

  Variables                               OS                   PFS                          
  --------------------------------------- -------------------- ------- -------------------- -------
  Sex (male vs. female)                   0.482(0.194-1.215)   0.122   0.535(0.212-1.351)   0.186
  Age (\<=57 vs. \>57)                    0.709(0.409-1.230)   0.221   1.206(0.693-2.100)   0.508
  TACE therapy (no vs. yes)               1.514(0.463-4.949)   0.492   0.786(0.244-2.533)   0.686
  Radiotherapy (no vs. yes)               0.703(0.398-1.242)   0.225   0.723(0.401-1.304)   0.281
  Surgery (no vs. yes)                    1.759(0.901-3.435)   0.098   1.074(0.539-2.139)   0.839
  DC-CTL therapy (no vs. yes)             1.928(1.117-3.327)   0.018   2.671(1.536-4.645)   0.001
  T (2 vs. 3,4)                           0.505(0.226-1.127)   0.095   0.811(0.363-1.812)   0.610
  N (0 vs. 1,2)                           1.308(0.737-2.321)   0.358   1.063(0.593-1.905)   0.837
  TNM Stage (IIA vs. IIB, IIC, III, IV)   0.578(0.229-1.460)   0.246   1.007(0.397-2.555)   0.988

Abbreviation: CI, confidence interval.
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